Last reviewed · How we verify
Nimotuzumab ( h-R3)
Nimotuzumab is a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) to inhibit tumor cell proliferation and survival.
Nimotuzumab is a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) to inhibit tumor cell proliferation and survival. Used for Head and neck squamous cell carcinoma, Non-small cell lung cancer, Colorectal cancer.
At a glance
| Generic name | Nimotuzumab ( h-R3) |
|---|---|
| Also known as | CIMAHOPE |
| Sponsor | El Kendi Pharmaceuticals Manufacturing Company |
| Drug class | EGFR inhibitor monoclonal antibody |
| Target | EGFR (Epidermal Growth Factor Receptor) |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Nimotuzumab binds to EGFR on cancer cells, preventing ligand-induced activation and downstream signaling that drives cell growth and division. Unlike some other anti-EGFR antibodies, it has a lower binding affinity that may reduce toxicity while maintaining anti-tumor activity. This mechanism is particularly relevant in cancers with EGFR overexpression.
Approved indications
- Head and neck squamous cell carcinoma
- Non-small cell lung cancer
- Colorectal cancer
Common side effects
- Acneiform rash
- Diarrhea
- Nausea
- Fatigue
- Infusion reactions
Key clinical trials
- A Trial of Nimotuzumab and Pinkiller Efficacy and Pain in Advanced Head and Neck Squamous Cell Carcinoma (PHASE4)
- Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma (PHASE3)
- Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer (PHASE2)
- SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer (PHASE2)
- Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure (PHASE2)
- Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer (PHASE2, PHASE3)
- Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis (PHASE2)
- Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nimotuzumab ( h-R3) CI brief — competitive landscape report
- Nimotuzumab ( h-R3) updates RSS · CI watch RSS
- El Kendi Pharmaceuticals Manufacturing Company portfolio CI